Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 11/20 | 0.96 |
| ▸ | CA12 | O43570 | 10/20 | 0.96 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.96 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.96 |
| ▸ | GLA | P06280 | 6/20 | 0.96 |
| ▸ | GAA | P10253 | 6/20 | 0.96 |
| ▸ | CA1 | P00915 | 6/20 | 0.96 |
| ▸ | HPGD | P15428 | 5/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.96 |
| ▸ | CASP1 | P29466 | 4/20 | 0.96 |
| ▸ | CASP7 | P55210 | 4/20 | 0.96 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.96 |
| ▸ | MEN1 | O00255 | 2/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Umbelliferone SCHEMBL22018 | 0.98 | CA9 (1.00) | CA9CA12MCL1KDM4EALDH1A1 | |
| Umbelliferone SCHEMBL11137587 | 0.98 | CA9 (1.00) | CA9CA12MCL1KDM4EALDH1A1 | |
| Umbelliferone SCHEMBL29396070 | 0.98 | CA9 (1.00) | CA9CA12MCL1KDM4EALDH1A1 | |
| Umbelliferone SCHEMBL29624448 | 0.98 | CA9 (1.00) | CA9CA12MCL1KDM4EALDH1A1 | |
| Umbelliferone SCHEMBL27427599 | 0.96 | CA9 (0.96) | CA9CA12MCL1KDM4EALDH1A1 | |
| Umbelliferone SCHEMBL2767044 | 0.96 | CA9 (0.96) | CA9CA12MCL1KDM4EALDH1A1 | |
| Umbelliferone SCHEMBL27915972 | 0.96 | CA9 (0.96) | CA9CA12MCL1KDM4EALDH1A1 | |
| Umbelliferone SCHEMBL27700116 | 0.96 | CA9 (0.96) | CA9CA12MCL1KDM4EALDH1A1 | |
| Umbelliferone SCHEMBL29001874 | 0.94 | CA9 (0.92) | CA9CA12MCL1KDM4EALDH1A1 | |
| Umbelliferone SCHEMBL27896245 | 0.94 | CA9 (0.92) | CA9CA12MCL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110025614-A | A kind of oral care composition and its purposes in treatment chronic oral inflammation | 牡丹江医学院 | 2019-07-19 | — | — | CN | disclosed |
| US-20170159105-A1 | Enzyme Assays on a Droplet Actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9574220-B2 | Enzyme assays on a droplet actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2516669-B1 | ENZYME ASSAYS ON A DROPLET ACTUATOR | ADVANCED LIQUID LOGIC INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20150184219-A1 | Enzyme Assays on a Droplet Actuator | ADVANCED LIQUID LOGIC, INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-9012165-B2 | Assay for B-galactosidase activity | ADVANCED LIQUID LOGIC, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140141460-A1 | Method of Conducting an Assay | ADVANCED LIQUID LOGIC, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8592217-B2 | Method of conducting an assay | ADVANCED LIQUID LOGIC, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20130130936-A1 | Method of Conducting an Assay | ADVANCED LIQUID LOGIC, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8394641-B2 | Method of hydrolyzing an enzymatic substrate | ADVANCED LIQUID LOGIC INC. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2516669-A2 | ENZYME ASSAYS ON A DROPLET ACTUATOR | Advanced Liquid Logic, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120136147-A1 | Method of hydrolyzing an enzymatic substrate | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-31 | — | — | US | disclosed |
| US-8093062-B2 | Enzymatic assays using umbelliferone substrates with cyclodextrins in droplets in oil | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-01-10 | — | — | US | disclosed |
| WO-2011084703-A2 | ENZYME ASSAYS ON A DROPLET ACTUATOR | ADVANCED LIQUID LOGIC, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110118132-A1 | Enzymatic Assays Using Umbelliferone Substrates with Cyclodextrins in Droplets of Oil | ADVANCED LIQUID LOGIC, INC. (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150184219-A1 | Enzyme Assays on a Droplet Actuator | IDE, UCHL3, UGDH | CA9 2300/4885CA12 2932/4885MCL1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.